Cargando…

Current Indications and Future Landscape of Bispecific Antibodies for the Treatment of Lung Cancer

Bispecific antibodies are a promising type of therapy for the treatment of cancer due to their ability to simultaneously inhibit different proteins playing a role in cancer progression. The development in lung cancer has been singularly intense because of the increasingly vast knowledge of the under...

Descripción completa

Detalles Bibliográficos
Autores principales:	Arasanz, Hugo, Chocarro, Luisa, Fernández-Rubio, Leticia, Blanco, Ester, Bocanegra, Ana, Echaide, Miriam, Labiano, Ibone, Huerta, Ana Elsa, Alsina, Maria, Vera, Ruth, Escors, David, Kochan, Grazyna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10298459/ https://www.ncbi.nlm.nih.gov/pubmed/37373003 http://dx.doi.org/10.3390/ijms24129855

Ejemplares similares

Leading Edge: Intratumor Delivery of Monoclonal Antibodies for the Treatment of Solid Tumors
por: Blanco, Ester, et al.
Publicado: (2023)

Immune Profiling Uncovers Memory T-Cell Responses with a Th17 Signature in Cancer Patients with Previous SARS-CoV-2 Infection Followed by mRNA Vaccination
por: Echaide, Miriam, et al.
Publicado: (2022)

Cutting-Edge: Preclinical and Clinical Development of the First Approved Lag-3 Inhibitor
por: Chocarro, Luisa, et al.
Publicado: (2022)

Cutting-Edge CAR Engineering: Beyond T Cells
por: Chocarro, Luisa, et al.
Publicado: (2022)

mRNA Vaccines against SARS-CoV-2: Advantages and Caveats
por: Echaide, Miriam, et al.
Publicado: (2023)

Understanding LAG-3 Signaling
por: Chocarro, Luisa, et al.
Publicado: (2021)

Systemic CD4 Immunity and PD-L1/PD-1 Blockade Immunotherapy
por: Escors, David, et al.
Publicado: (2022)

PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy
por: Bocanegra, Ana, et al.
Publicado: (2020)

Systemic Blood Immune Cell Populations as Biomarkers for the Outcome of Immune Checkpoint Inhibitor Therapies
por: Hernandez, Carlos, et al.
Publicado: (2020)

Systemic CD4 immunity: A powerful clinical biomarker for PD‐L1/PD‐1 immunotherapy
por: Zuazo, Miren, et al.
Publicado: (2020)

Systemic CD4 Immunity as a Key Contributor to PD-L1/PD-1 Blockade Immunotherapy Efficacy
por: Zuazo, Miren, et al.
Publicado: (2020)

Clinical landscape of LAG-3-targeted therapy
por: Chocarro, L., et al.
Publicado: (2022)

CAR-T Cells for the Treatment of Lung Cancer
por: Chocarro, Luisa, et al.
Publicado: (2022)

Hyperprogressive Disease: Main Features and Key Controversies
por: Arasanz, Hugo, et al.
Publicado: (2021)

Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon?
por: Chocarro de Erauso, Luisa, et al.
Publicado: (2020)

How Can We Improve the Vaccination Response in Older People? Part II: Targeting Immunosenescence of Adaptive Immunity Cells
por: Garnica, Maider, et al.
Publicado: (2022)

How Can We Improve Vaccination Response in Old People? Part I: Targeting Immunosenescence of Innate Immunity Cells
por: Aiello, Anna, et al.
Publicado: (2022)

State of the Art: ctDNA in Upper Gastrointestinal Malignancies
por: Labiano, Ibone, et al.
Publicado: (2023)

Circulating Low Density Neutrophils Are Associated with Resistance to First Line Anti-PD1/PDL1 Immunotherapy in Non-Small Cell Lung Cancer
por: Arasanz, Hugo, et al.
Publicado: (2022)

Profound Reprogramming towards Stemness in Pancreatic Cancer Cells as Adaptation to AKT Inhibition
por: Arasanz, Hugo, et al.
Publicado: (2020)

Metabolic dyshomeostasis induced by SARS-CoV-2 structural proteins reveals immunological insights into viral olfactory interactions
por: Lachén-Montes, Mercedes, et al.
Publicado: (2022)

Systemic immunological biomarkers of clinical responses in immune checkpoint blockade therapies
por: Arasanz, Hugo, et al.
Publicado: (2018)

Early Detection of Hyperprogressive Disease in Non-Small Cell Lung Cancer by Monitoring of Systemic T Cell Dynamics
por: Arasanz, Hugo, et al.
Publicado: (2020)

A Proteomic Atlas of Lineage and Cancer-Polarized Expression Modules in Myeloid Cells Modeling Immunosuppressive Tumor-Infiltrating Subsets
por: Blanco, Ester, et al.
Publicado: (2021)

The intracellular signalosome of PD-L1 in cancer cells
por: Escors, David, et al.
Publicado: (2018)

Plasma fractalkine contributes to systemic myeloid diversity and PD‐L1/PD‐1 blockade in lung cancer
por: Bocanegra, Ana, et al.
Publicado: (2023)

PD1 signal transduction pathways in T cells
por: Arasanz, Hugo, et al.
Publicado: (2017)

Functional systemic CD4 immunity is required for clinical responses to PD‐L1/PD‐1 blockade therapy
por: Zuazo, Miren, et al.
Publicado: (2019)

PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung Cancer
por: Bocanegra, Ana, et al.
Publicado: (2019)

Cell and Tissue Gene Targeting with Lentiviral Vectors
por: Escors, David, et al.
Publicado: (2012)

The multi-specific V(H)-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activity
por: Edwards, Carolyn J., et al.
Publicado: (2021)

Role of non-classical MHC class I molecules in cancer immunosuppression
por: Kochan, Grazyna, et al.
Publicado: (2013)

A core of kinase-regulated interactomes defines the neoplastic MDSC lineage
por: Gato-Cañas, Maria, et al.
Publicado: (2015)

Prolonged disease control with local treatments in oligo-acquired resistance to immune-checkpoint inhibitors
por: Arasanz, Hugo, et al.
Publicado: (2023)

The landscape of bispecific T cell engager in cancer treatment
por: Zhou, Shujie, et al.
Publicado: (2021)

Generation and characterization of monospecific and bispecific hexavalent trimerbodies
por: Blanco-Toribio, Ana, et al.
Publicado: (2013)

Research and Clinical Landscape of Bispecific Antibodies for the Treatment of Solid Malignancies
por: Antonarelli, Gabriele, et al.
Publicado: (2021)

Current landscape and future directions of bispecific antibodies in cancer immunotherapy
por: Wei, Jing, et al.
Publicado: (2022)

Bispecific Immunomodulatory Antibodies for Cancer Immunotherapy
por: Blanco, Belén, et al.
Publicado: (2021)

T‐cell redirecting bispecific antibodies in multiple myeloma: Current landscape and future directions
por: O'Neill, Chloe, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_pr6ufap2mph6p474b6b3m0j2t2